Blog Category

Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and distribution agr...

December 1st, 2020

Read article

Helsinn receives Swiss Biotech Success Stories Award 2020

October 6th, 2020

Read article

Helsinn supports the PhD program 2020-2021 of the Institute of Oncology Research...

September 23rd, 2020

Read article

Helsinn Group and Italfarmaco announce oral presentation of NEPA (netupitant and...

September 18th, 2020

A Phase 3 study concludes that a simplified regimen of one dose of NEPA and dexamethasone (DEX) has comparable anti-emetic efficacy to regimens with g...

Read article

Helsinn Group announces AKYNZEO® injection – a new liquid IV solution -- now ava...

August 20th, 2020

Read article

Helsinn Advanced Synthesis opens its largest dedicated Anticancer bay

July 30th, 2020

Read article

3B Future Health Fund announces new investment in iOnctura

July 14th, 2020

Read article

Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in A...

July 2nd, 2020

Read article

Helsinn Group supports Conquer Cancer, the ASCO Foundation’s COVID Impacts Cance...

June 10th, 2020

Read article

Helsinn announces launch of oral formulation of Akynzeo® in China

June 9th, 2020

Read article

Helsinn announces FDA acceptance of IND application for TAS0953/HM06 in Patients...

June 8th, 2020

Read article

Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fo...

June 2nd, 2020

Read article

Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Eva...

May 13th, 2020

Data to be Featured in the American Society of Clinical Oncology Annual 2020 Virtual Scientific Program on May 29, 2020 at 8:00 a.m. EDT

Read article

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VAL...

April 20th, 2020

Read article

Helsinn announces European approval of the IV formulation of AKYNZEO® (fosnetupi...

March 23rd, 2020

Read article

New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress...

February 14th, 2020

Read article

Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn C...

January 31st, 2020

Read article

Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company o...

January 27th, 2020

Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® (ALOXI®) in Russia and CIS reg...

Read article

Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn...

January 14th, 2020

The Award recognizes Patient Entrepreneurs demonstrating outstanding innovations which advance solutions in the prevention, management or care of canc...

Read article

Helsinn appoints Eric Cornut and Lonnie Moulder to the Board of Directors

January 13th, 2020

Read article